PHASEBIO PHARMA Current Ratio 2018-2021 | PHAS

PHASEBIO PHARMA current ratio from 2018 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
PHASEBIO PHARMA Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.09B $0.02B 5.47
2021-03-31 $0.09B $0.02B 5.29
2020-12-31 $0.04B $0.02B 2.68
2020-09-30 $0.05B $0.01B 4.39
2020-06-30 $0.06B $0.02B 3.58
2020-03-31 $0.07B $0.01B 9.68
2019-12-31 $0.08B $0.01B 9.30
2019-09-30 $0.08B $0.01B 13.98
2019-06-30 $0.10B $0.01B 16.52
2019-03-31 $0.05B $0.00B 14.24
2018-12-31 $0.06B $0.01B 13.68
2018-09-30 $0.03B $0.01B 3.25
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B 0.00
2017-09-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.145B $0.000B
PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71